Cartesian Therapeutics
RNAC
79 hedge funds and large institutions have $144M invested in Cartesian Therapeutics in 2020 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 24 increasing their positions, 26 reducing their positions, and 16 closing their positions.
272% more call options, than puts
Call options by funds: $361K | Put options by funds: $97K
0.42% less ownership
Funds ownership: 2.34% → 1.91% (-0.42%)
8% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 26
2% less funds holding
Funds holding: 81 → 79 (-2)
13% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 16
17% less capital invested
Capital invested by funds: $174M → $144M (-$30.4M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
+$4.09M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$2.61M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.49M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$1.66M |
| 5 |
Two Sigma Advisers
New York
|
+$1.57M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$3.34M |
| 2 |
GTC
Ghost Tree Capital
New York
|
-$2.84M |
| 3 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$1.94M |
| 4 |
Renaissance Technologies
New York
|
-$1.64M |
| 5 |
BBVA
Banco Bilbao Vizcaya Argentaria
Madrid,
Spain
|
-$1.54M |
RNAC Hedge Fund Activity: Q3 2020 in Review
79 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Cartesian Therapeutics (RNAC) for Q3 2020, worth a combined $144M — down 17% from $174M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of RNAC and 14 opened new positions — a net loss of 2 holders — while 26 trimmed existing stakes and 24 added.
The largest buyer was Artal Group, adding an estimated $4.09M. The largest seller was Vivo Capital, cutting an estimated $3.34M.
- 79 institutional investors held Cartesian Therapeutics (RNAC) as of Q3 2020, down from 81 in Q2 2020.
- Funds reported $144M of Cartesian Therapeutics stock for Q3 2020, down 17% quarter-over-quarter.
- 14 funds opened new Cartesian Therapeutics positions in Q3 2020 and 16 closed out, a net change of -2 holders.
- The largest Cartesian Therapeutics buyer in Q3 2020 was Artal Group, an estimated $4.09M added.
- The largest Cartesian Therapeutics seller in Q3 2020 was Vivo Capital, an estimated $3.34M sold.
Based on aggregated 13F filings for Q3 2020.